Posted by Michael Wonder on 09 Aug 2024
Citius Pharmaceuticals receives FDA approval for Lymphir (denileukin diftitox-cxdl) immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma
8 August 2024 - Lymphir is expected to launch within the next five months.
Citius Pharmaceuticals announced today that the US FDA has approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed/refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.
